Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced the appointment of Dr. Mark Carnegie-Brown as its Chief Executive Officer.
Dr. Carnegie-Brown brings to Glide 25 years’ experience of the life sciences sector. Previously, he was CEO of Evolutec, a biological drug development business, where he led a successful IPO and established the company’s clinical and manufacturing programmes. He was also CEO of Aenova, a pharmaceutical tablet and capsule manufacturer, where he led the integration of the Swisscaps and Dragenopharm organisations. Dr. Carnegie-Brown started his career in R&D at ICI and subsequently held a number of commercial roles before becoming General Manager of Zeneca’s UK and Eire business.
“I am delighted to welcome Mark to Glide Pharma,” said Mark Kirby, Glide Pharma’s Chairman. “His research and commercial experience, and in particular his expertise in building successful clinical and manufacturing programmes, will prove invaluable as Glide scales up its capabilities and advances the development of its in-house programmes. I would also like to take this opportunity to thank Dr Ian Smith, our previous CEO, for his contribution to the success of Glide, and I look forward to his continuing support as a member of the company’s Board.”
“Glide is in a truly transformational period in its development, and I am delighted to have this opportunity to lead the organisation,” said Dr. Mark Carnegie-Brown, Glide Pharma’s CEO. “Having recently completed a successful major fundraising and received significant funding from the UK government-backed Biomedical Catalyst, Glide is well positioned for growth, and I look forward to leading the team as we accelerate the development of the company’s solid dose delivery technology.”